Europe's Agritech Crown Is Slipping: What the Netherlands' $18B Warning Means for Founders

Jan de Vries · 2026-10-30

The Netherlands has long been the quiet overachiever of European agriculture. Tiny country, massive output. But a new report from Invest-NL, the Dutch national investment institution, suggests that crown is starting to wobble. And if you're building in agritech or food biotech, the reasons why should get your attention. ### The $18 Billion Opportunity Hiding in Plain Sight The report, called *Deep Dive Agrifood Biotech*, puts a number on what's at stake: about $18 billion (€17 billion) in additional annual revenue by 2040. That's not pocket change. But here's the catch—it only happens if the country gets its act together on regulation, financing, and commercialisation. Otherwise, that money flows to Brazil, the US, or wherever else moves faster. Invest-NL didn't just crunch numbers. They talked to over 150 entrepreneurs, investors, researchers, and policymakers. They looked at investment data from 2010 through April 2026. And they focused on three areas: seed breeding and genetics, biological agricultural inputs, and biotech-derived food ingredients. ### A Strong Start, a Weak Finish The Netherlands has world-class research institutions and a sophisticated food production ecosystem. So why isn't that translating into global giants? The report points to a telling imbalance. The country accounts for 3.3% of BioTech startups worldwide—but only 1.3% of scale-ups. In other words, they're great at starting companies and less great at growing them. Invest-NL names three recurring weaknesses: - Too few promising technologies become scalable ventures. - Regulatory and validation processes delay market entry. - Insufficient financing prevents companies from reaching industrial production. The stakes are high. In a favourable scenario, annual Dutch agrifood BioTech revenues could hit $26 billion (€25 billion) by 2040. Under current conditions? Just $8–9 billion (€8–9 billion). That's a massive gap. ### Ten Years to Say Yes One of the most frustrating bottlenecks is biological crop protection. Dutch companies are developing alternatives to chemical pesticides. But getting European regulatory approval can take eight to ten years. Why? Because existing frameworks were designed for chemicals, not biology. So some companies launch in Brazil or the US first, where things move faster. Invest-NL warns that Europe could lose ground in a market that might expand seven- to tenfold by 2040. Food biotechnology faces similar hurdles. Novel ingredients take one to three years longer to approve in Europe than in the US. And building a first commercial production facility? Tens or hundreds of millions of euros. For fermentation-derived ingredients alone, favourable conditions could support $8.3 billion (€8 billion) in annual Dutch revenues by 2040—versus $2.1 billion (€2 billion) under current policies. ### It's Not About Manufacturing Everything Here's a key insight: the Netherlands doesn't need to make everything at home. Instead, it should focus on keeping the knowledge, intellectual property, and specialised capabilities—while tapping into European production networks where it makes sense. That's a smarter, more realistic play. The report also stresses that faster approvals shouldn't come at the cost of safety. Regulators should offer earlier guidance, more predictable assessments, and chances to validate products in real-world conditions. Innovation isn't the problem. Turning it into scalable businesses is. And that's a lesson every founder in deep tech should take to heart.